Acquisition of Secucinumab and Ofatumumab

This tender is for the procurement of two specific pharmaceutical products: Secucinumab and Ofatumumab. These are high-value biologic medications, typically used in the treatment of specific autoimmune and inflammatory conditions, such as psoriasis, psoriatic arthritis, ankylosing spondylitis (for Secucinumab), and certain types of multiple sclerosis and eye conditions (for Ofatumumab). The acquisition aims to ensure the availability of these critical treatments for patients who require them. The tender process will likely involve sourcing these specialized drugs from authorized suppliers, ensuring compliance with all regulatory and quality standards. The objective is to secure a reliable supply chain for these important medications, guaranteeing that healthcare providers can prescribe and administer them to patients without interruption. This procurement highlights the commitment to providing advanced therapeutic options for complex medical conditions.

This is a supplies contract in the health and medical services, trade and industry and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 28,925.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.